4D Molecular Therapeutics, Inc. (FDMT) Tops Q1 EPS by 1c

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) reported Q1 EPS of ($0.88), $0.01 better than the analyst estimate of ($0.89). Revenue for the quarter came in at $300 thousand versus the consensus estimate of $1.03 million.

For earnings history and earnings-related data on 4D Molecular Therapeutics, Inc. (FDMT) click here.

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• Bernstein remains bullish on SpaceX but sees challenges in telecom ambitions
• Investing.com’s stocks of the week